Share

2022 Biotech Investing Forecast

After what has undoubtedly been a very rocky 12 months for biotech, is the sector ripe for a comeback? Biotech investor and Harvard-trained medical doctor, Dr. Christiana Bardon thinks advances in gene therapies, robust drug pipelines and an improving regulatory landscape will be key industry drivers for the road ahead.
06:37
Fri, Apr 15 202212:01 AM EDT